

## Supplementary Material

# **Engineered Hybrid Cell Membrane Nanovesicles for Potentiated Cancer Immunotherapy through Dual Immune Checkpoint Inhibition**


Fuxu Yang<sup>a,b#</sup>, Han Xue<sup>b#</sup>, Yuxin Fan<sup>b#</sup>, Ting Zhang<sup>a</sup>, Ting Wang<sup>a</sup>, Fanlin Gu<sup>b</sup>,  
Longxue Guan<sup>b</sup>, Lisha Zhou<sup>a,\*</sup>, Xingang Guan<sup>a,\*</sup>, Guofu Chen<sup>a,\*</sup>

<sup>a</sup> The First People's Hospital of Wenling (Taizhou University Affiliated Wenling Hospital), School of Medicine, Taizhou University, Taizhou 317500, PR China


<sup>b</sup> College of Medical Technology, Beihua University, Jilin 132013, PR China

**Corresponding authors:** lishazhou@tzc.edu.cn (L. Zhou); guanxg@ciac.ac.cn (X. Guan), wlcgf@163.com (G. Chen).


# These authors contribute to this work equally.




**Figure S1.** CLSM imaging (A) and western blot analysis (B) of PD-1-GFP stable cell lines. The nucleus was stained with DAPI (indicated in blue), and the PD-1 receptor was represented in green. Total protein from HEK-293T cells or HEK-293T-PD-1 cells was used for western blot analysis. Antibodies targeting mouse PD-1 was used.




**Figure S2.** CLSM imaging (A) and western blot analysis (B) of LAG-3-mCherry stable cell lines. The nucleus was stained with DAPI (indicated in blue), and the LAG-3 receptor was represented in red. Total protein from HEK-293T cells or HEK-293T-LAG-3 cells was used for western blot analysis. Antibodies targeting mouse LAG-3 was used.




**Figure S3.** Histological images for H&E staining obtained from the liver, spleen, kidney, heart, and lung of mice with different treatments. Scale bar: 100  $\mu$ m.




**Figure S4.** Serum biochemical analysis of kidney and liver function parameters. Data are expressed as mean  $\pm$  SD (n=3). The levels of ALT (Figure S8A), AST (Figure S8B), UA (Figure S8C), Urea (Figure S8D), and Crea (Figure S8E) in the supernatants were determined.



**Figure S5.** Flow cytometry gating strategies for CD8<sup>+</sup> T cells in tumors. The cells were gated for positive CD45<sup>+</sup>CD8<sup>+</sup> expression.



**Figure S6.** Flow cytometry gating strategies for perforin or GZMB positive CD8<sup>+</sup> T cells in tumors. The cells were gated for positive CD45<sup>+</sup>CD8<sup>+</sup> expression.




**Figure S7.** Flow cytometry gating strategies for dendritic cells in tumors. The cells were gated for positive CD80<sup>+</sup>CD86<sup>+</sup> expression.





**Figure S8.** Flow cytometry gating strategies for Treg cells in tumors. The cells were gated for positive CD45<sup>+</sup>CD4<sup>+</sup>Foxp3<sup>+</sup> expression.



**Figure S9.** Uncropped and unprocessed images used in Figure 2B in this study.